Procedure: biospecimen collection (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 159 | Xeroderma pigmentosum | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04500548 (ClinicalTrials.gov) | February 26, 2021 | 4/8/2020 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | 3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent, and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers | Constitutional Mismatch Repair Deficiency Syndrome;Hematopoietic and Lymphoid Cell Neoplasm;Lynch Syndrome;Recurrent Lymphoma;Recurrent Malignant Solid Neoplasm;Recurrent Neuroblastoma;Recurrent Primary Central Nervous System Neoplasm;Refractory Lymphoma;Refractory Malignant Solid Neoplasm;Refractory Neuroblastoma;Refractory Primary Central Nervous System Neoplasm;Xeroderma Pigmentosum | Procedure: Biospecimen Collection;Biological: Ipilimumab;Biological: Nivolumab | National Cancer Institute (NCI) | NULL | Not yet recruiting | 12 Months | 25 Years | All | 40 | Phase 1 | NULL |